Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.

Heiblig M, Labussière-Wallet H, Nicolini FE, Michallet M, Hayette S, Sujobert P, Plesa A, Balsat M, Paubelle E, Barraco F, Tigaud I, Ducastelle S, Wattel E, Salles G, Thomas X.

Cancers (Basel). 2019 Apr 22;11(4). pii: E570. doi: 10.3390/cancers11040570.

2.

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.

Dulucq S, Etienne G, Morisset S, Klein E, Chollet C, Robbesyn F, Turcq B, Tigaud I, Hayette S, Nicolini FE, Mahon FX.

Ann Hematol. 2019 May;98(5):1159-1168. doi: 10.1007/s00277-019-03633-x. Epub 2019 Feb 23.

PMID:
30798348
3.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

4.

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life.

Huet S, Paubelle E, Lours C, Grange B, Courtois L, Chabane K, Charlot C, Mosnier I, Simonet T, Hayette S, Tigaud I, Thomas X, Salles G, Subtil F, Sujobert P.

Blood. 2018 Aug 23;132(8):865-867. doi: 10.1182/blood-2018-03-840348. Epub 2018 Jun 4. No abstract available.

PMID:
29866812
5.

Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.

Collinge E, Tigaud I, Balme B, Gerland LM, Sujobert P, Carlioz V, Salles G, Thomas X, Paubelle E.

Medicine (Baltimore). 2018 Feb;97(8):e9657. doi: 10.1097/MD.0000000000009657.

6.

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia.

Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, Labussierre H, Ducastelle S, Paubelle E, Nicolini FE, Elhamri M, Campos L, Plesa C, Morisset S, Salles G, Bertrand Y, Michallet M, Thomas X.

World J Stem Cells. 2017 Dec 26;9(12):227-234. doi: 10.4252/wjsc.v9.i12.227.

7.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.

8.

Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.

Quintela A, Sujobert P, Tigaud I, Hayette S, Ffrench M, Salles G, Thomas X, Plesa A.

Oncol Ther. 2017;5(1):111-118. doi: 10.1007/s40487-017-0041-7. Epub 2017 Feb 9.

9.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.

PMID:
28167452
10.

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia.

Heiblig M, Paubelle E, Plesa A, Geay MO, Manzoni D, Gazzo S, Tigaud I, Callet-Bauchu E, Huet S, Salles G, Thomas X, Hayette S, Sujobert P.

Blood. 2017 Jan 5;129(1):128-131. doi: 10.1182/blood-2016-09-741355. Epub 2016 Nov 8. No abstract available.

11.

Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Eclache V, Lafage-Pochitaloff M, Lefebvre C, Penther D, Raynaud S, Tigaud I.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):525-534. Review.

PMID:
27546835
12.

Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.

Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, Salles G, Thomas X.

Leuk Lymphoma. 2017 Jan;58(1):110-117. Epub 2016 May 17.

PMID:
27184036
13.

Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience.

Heiblig M, Elhamri M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Michallet M, Nicolini F, Plesa C, Wattel E, Salles G, Thomas X.

Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016009. doi: 10.4084/MJHID.2016.009. eCollection 2016.

14.

Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia.

Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, Thomas X.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):477-83. doi: 10.1016/j.clml.2015.02.022. Epub 2015 Mar 5.

PMID:
25843415
15.

Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL.

Bond J, Bergon A, Durand A, Tigaud I, Thomas X, Asnafi V, Spicuglia S, Macintyre E.

Blood. 2014 Nov 6;124(19):3023-5. doi: 10.1182/blood-2014-04-567636. No abstract available.

16.

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F.

PLoS One. 2014 Sep 9;9(9):e106250. doi: 10.1371/journal.pone.0106250. eCollection 2014.

17.

Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.

Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X.

Leuk Lymphoma. 2015 Mar;56(3):622-9. doi: 10.3109/10428194.2014.927453. Epub 2014 Jul 17.

PMID:
24884314
18.

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.

Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A, Etienne M, Hayette S, Lippert E, Bureau C, Tigaud I, Adiko D, Marit G, Reiffers J, Mahon FX.

Haematologica. 2014 Mar;99(3):458-64. doi: 10.3324/haematol.2013.095158. Epub 2013 Dec 20.

19.

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Clément C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L.

Blood. 2013 Oct 24;122(17):3082-4. doi: 10.1182/blood-2013-07-513879. No abstract available.

20.

Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature.

Chapiro E, Radford-Weiss I, Cung HA, Dastugue N, Nadal N, Taviaux S, Barin C, Struski S, Talmant P, Vandenberghe P, Mozziconacci MJ, Tigaud I, Lefebvre C, Penther D, Bastard C, Lippert E, Mugneret F, Romana S, Bernard OA, Harrison CJ, Russell LJ, Nguyen-Khac F; Groupe Francophone de Cytogénétique Hématologique.

Cancer Genet. 2013 May;206(5):162-73. doi: 10.1016/j.cancergen.2013.04.004. Epub 2013 Jul 1. Review.

PMID:
23827691
21.

Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia.

Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C; French ALFA group.

Am J Hematol. 2013 Apr;88(4):306-11. doi: 10.1002/ajh.23403. Epub 2013 Mar 5.

22.

High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.

Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, Cornillet-Lefebvre P, Plesa A, Huet S, Renneville A, Salles G, Nicolini FE, Magaud JP, Michallet M.

PLoS One. 2012;7(12):e51527. doi: 10.1371/journal.pone.0051527. Epub 2012 Dec 10.

23.

Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.

Havelange V, Ameye G, Théate I, Callet-Bauchu E, Mugneret F, Michaux L, Dastugue N, Penther D, Barin C, Collonge-Rame MA, Baranger L, Terré C, Nadal N, Lippert E, Laï JL, Cabrol C, Tigaud I, Herens C, Hagemeijer A, Raphael M, Libouton JM, Poirel HA; GFCH (Groupe Francophone de Cytogénétique Hématologique).

Genes Chromosomes Cancer. 2013 Jan;52(1):81-92. doi: 10.1002/gcc.22008. Epub 2012 Sep 25.

PMID:
23012230
24.

PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.

Duhoux FP, Ameye G, Montano-Almendras CP, Bahloula K, Mozziconacci MJ, Laibe S, Wlodarska I, Michaux L, Talmant P, Richebourg S, Lippert E, Speleman F, Herens C, Struski S, Raynaud S, Auger N, Nadal N, Rack K, Mugneret F, Tigaud I, Lafage M, Taviaux S, Roche-Lestienne C, Latinne D, Libouton JM, Demoulin JB, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO).

Br J Haematol. 2012 Jan;156(1):76-88. doi: 10.1111/j.1365-2141.2011.08918.x. Epub 2011 Nov 3.

PMID:
22050763
25.

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.

Duhoux FP, Ameye G, Lambot V, Herens C, Lambert F, Raynaud S, Wlodarska I, Michaux L, Roche-Lestienne C, Labis E, Taviaux S, Chapiro E, Nguyen-Khac F, Struski S, Dobbelstein S, Dastugue N, Lippert E, Speleman F, Van Roy N, De Weer A, Rack K, Talmant P, Richebourg S, Mugneret F, Tigaud I, Mozziconacci MJ, Laibe S, Nadal N, Terré C, Libouton JM, Decottignies A, Vikkula M, Poirel HA; Groupe Francophone de Cytogénétique Hématologique (GFCH); Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO).

PLoS One. 2011;6(10):e26311. doi: 10.1371/journal.pone.0026311. Epub 2011 Oct 21. Erratum in: PLoS One. 2011 Dec 13;6(12). doi: 10.1371/annotation/3b5aaa87-72b6-49d3-9ec9-f4a656e12e3a. Khac, Florence Nguyen [corrected to Nguyen-Khac, Florence].

26.

Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?

Thomas X, Chelghoum Y, Cannas G, Elhamri M, Labussière H, Tigaud I, Ducastelle S, Nicolini F, Dumontet C, Michallet M.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):342-9. doi: 10.1016/j.clml.2011.06.003.

PMID:
21816372
27.

Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases.

Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, Dumontet C, Michallet M, Thomas X.

Leuk Res. 2011 Aug;35(8):1027-31. doi: 10.1016/j.leukres.2011.02.015. Epub 2011 Mar 12.

PMID:
21397944
28.

The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.

Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, Nicolas-Virelizier E, Michallet M, Tigaud I, Magaud JP, Turhan A, Guilhot F, Hayette S.

Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):394-9. doi: 10.3816/CLML.2010.n.073.

PMID:
21030353
29.

Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.

Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S, Gachard N, Tigaud I, Dastugue N, Huguet F, Fort MP, Legros L, Eclache V, Mahon FX.

Haematologica. 2010 Sep;95(9):1604-7. doi: 10.3324/haematol.2009.019109. Epub 2010 Apr 30.

30.

Indirubin derivatives inhibit malignant lymphoid cell proliferation.

Chebel A, Kagialis-Girard S, Catallo R, Chien WW, Mialou V, Domenech C, Badiou C, Tigaud I, Ffrench M.

Leuk Lymphoma. 2009 Dec;50(12):2049-60. doi: 10.3109/10428190903288449.

PMID:
19860623
31.

Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages.

Chapiro E, Leporrier N, Radford-Weiss I, Bastard C, Mossafa H, Leroux D, Tigaud I, De Braekeleer M, Terré C, Brizard F, Callet-Bauchu E, Struski S, Veronese L, Fert-Ferrer S, Taviaux S, Lesty C, Davi F, Merle-Béral H, Bernard OA, Sutton L, Raynaud SD, Nguyen-Khac F.

Leuk Res. 2010 Jan;34(1):63-8. doi: 10.1016/j.leukres.2009.03.042. Epub 2009 Apr 29.

PMID:
19406473
32.

Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases.

Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adélaïde J, Struski S, Lippert E, Mugneret F, Tigaud I, Penther D, Bastard C, Poppe B, Speleman F, Baranger L, Luquet I, Cornillet-Lefebvre P, Nadal N, Nguyen-Khac F, Pérot C, Olschwang S, Bertucci F, Chaffanet M, Lessard M, Mozziconacci MJ, Birnbaum D; Groupe Francophone de Cytogénétique Hématologique.

Leukemia. 2009 Jan;23(1):85-94. doi: 10.1038/leu.2008.257. Epub 2008 Sep 25.

PMID:
18818702
33.

Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique.

Gervais C, Murati A, Helias C, Struski S, Eischen A, Lippert E, Tigaud I, Penther D, Bastard C, Mugneret F, Poppe B, Speleman F, Talmant P, VanDen Akker J, Baranger L, Barin C, Luquet I, Nadal N, Nguyen-Khac F, Maarek O, Herens C, Sainty D, Flandrin G, Birnbaum D, Mozziconacci MJ, Lessard M; Groupe Francophone de Cytogénétique Hématologique.

Leukemia. 2008 Aug;22(8):1567-75. doi: 10.1038/leu.2008.128. Epub 2008 Jun 5.

PMID:
18528428
34.

Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.

Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, Ffrench M.

Leuk Res. 2008 Oct;32(10):1608-10. doi: 10.1016/j.leukres.2008.03.004. Epub 2008 Apr 29.

PMID:
18448166
35.

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Laï JL, Nicolini FE, Preudhomme C; Fi-LMC group.

Blood. 2008 Apr 1;111(7):3735-41. doi: 10.1182/blood-2007-07-102533. Epub 2008 Jan 17.

36.

Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.

Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X.

Cancer. 2008 Feb 1;112(3):572-80.

37.

[Treatment of chronic myeloid leukemia in 2007].

Labussière H, Hayette S, Tigaud I, Michallet M, Nicolini FE.

Bull Cancer. 2007 Oct;94(10):863-9. Review. French.

38.

Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH).

Luquet I, Laï JL, Barin C, Baranger L, Bilhou-Nabera C, Lippert E, Gervais C, Talmant P, Cornillet-Lefebvre P, Perot C, Nadal N, Mozziconacci MJ, Lafage-Pochitaloff M, Eclache V, Mugneret F, Lefebvre C, Herens C, Speleman F, Poirel H, Tigaud I, Cabrol C, Rousselot P, Daliphard S, Imbert M, Garand R, Geneviève F, Berger R, Terre C; Francophone de Cytogenetique Hematologique.

Leukemia. 2008 Jan;22(1):132-7. Epub 2007 Oct 11.

PMID:
17928884
39.

Inhibition of normal lymphocyte proliferation by Indirubin-3'-monoxime: a multifactorial process.

Kagialis-Girard S, Mialou V, Chebel A, Chien WW, Tigaud I, Mokdad F, Badiou C, Ffrench M.

Leuk Lymphoma. 2007 Mar;48(3):605-15.

PMID:
17454606
40.

BCR-ABL mutant kinetics in CML patients treated with dasatinib.

Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S.

Leuk Res. 2007 Jun;31(6):865-8. Epub 2007 Jan 8.

PMID:
17208297
41.

Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome.

Jaff N, Chelghoum Y, Elhamri M, Tigaud I, Michallet M, Thomas X.

Leuk Res. 2007 Jan;31(1):67-73. Epub 2006 Jun 30.

PMID:
16814381
42.

NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique.

Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N, Talmant P, Bilhou-Nabera C, Mugneret F, Lafage-Pochitaloff M, Mozziconacci MJ, Andrieu J, Lai JL, Terre C, Rack K, Cornillet-Lefebvre P, Luquet I, Nadal N, Nguyen-Khac F, Perot C, Van den Akker J, Fert-Ferrer S, Cabrol C, Charrin C, Tigaud I, Poirel H, Vekemans M, Bernard OA, Berger R; Groupe Francophone de Cytogénétique Hématologique.

Leukemia. 2006 Apr;20(4):696-706.

PMID:
16467868
43.
44.

Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.

Cayuela JM, Rousselot P, Nicolini F, Espinouse D, Ollagnier C, Bui-Thi MH, Chabane K, Raffoux E, Callet-Bauchu E, Tigaud I, Magaud JP, Hayette S.

Leukemia. 2005 Dec;19(12):2334-6. No abstract available.

PMID:
16224485
45.

AF4p12, a human homologue to the furry gene of Drosophila, as a novel MLL fusion partner.

Hayette S, Cornillet-Lefebvre P, Tigaud I, Struski S, Forissier S, Berchet A, Doll D, Gillot L, Brahim W, Delabesse E, Magaud JP, Rimokh R.

Cancer Res. 2005 Aug 1;65(15):6521-5.

46.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM, Terre C, Tigaud I, Castaigne S, Raffoux E, De Botton S, Fenaux P, Dombret H, Preudhomme C.

Blood. 2005 Nov 15;106(10):3618-20. Epub 2005 Jul 26.

47.

Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report.

Hayette S, Tigaud I, Thomas X, French M, Perrin MC, Nicolini F, Michallet M, Magaud JP.

Leukemia. 2004 Oct;18(10):1735-6. No abstract available.

PMID:
15356652
48.

Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics.

Roche J, Zeng C, Barón A, Gadgil S, Gemmill RM, Tigaud I, Thomas X, Drabkin HA.

Leukemia. 2004 Jun;18(6):1059-63.

PMID:
15085154
49.

In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene.

Hayette S, Tigaud I, Callet-Bauchu E, Ffrench M, Gazzo S, Wahbi K, Callanan M, Felman P, Dumontet C, Magaud JP, Rimokh R.

Blood. 2003 Aug 15;102(4):1549-50. No abstract available.

50.

FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress.

Libura M, Asnafi V, Tu A, Delabesse E, Tigaud I, Cymbalista F, Bennaceur-Griscelli A, Villarese P, Solbu G, Hagemeijer A, Beldjord K, Hermine O, Macintyre E.

Blood. 2003 Sep 15;102(6):2198-204. Epub 2003 Jun 5.

Supplemental Content

Loading ...
Support Center